Developing new inhaled therapies for tuberculosis treatment
Official title: Inhalational therapy with spectinamides within new regimens of TB therapy
Funded at Colorado State University · NIH-10918543 · Data updated 2026-11-12
This study is looking for better ways to treat tuberculosis (TB) by testing new combinations of medicines that are easier to take and work faster, so patients can feel better with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Colorado State University NIH-funded |
| Lab location | 1 site (Fort Collins, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $817,405 |
| NIH project number | 1R01AI178885-01A1 |
| Project ID | NIH-10918543 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with drug-sensitive or multidrug-resistant tuberculosis.
✕Less likely to help
Patients with non-tuberculosis related respiratory conditions or those who are not infected with TB may not benefit from this research.
What this research studies
This research aims to create shorter and safer therapies for tuberculosis (TB) that require fewer pills and have a reduced duration of treatment. The approach involves testing new drug combinations in preclinical models before moving to clinical trials. One promising strategy is to replace a commonly used drug with spectinamides, which can be administered via aerosol and have shown effectiveness against various strains of TB. The goal is to improve patient outcomes by minimizing adverse effects while maintaining efficacy.
Why it matters
Potential benefit: If successful, this research could lead to more effective and tolerable treatments for tuberculosis, reducing the burden on patients.
How similar studies have gone: Previous research has successfully developed effective TB regimens using similar approaches, indicating potential for success in this novel treatment strategy.
Where this research is happening
-
Colorado State University
Fort Collins, United States Active
Researchers
- Principal investigator: Gonzalez-Juarrero, Mercedes — Colorado State University
- Study coordinator: Gonzalez-Juarrero, Mercedes
Related research
Other NIH-funded projects on the same topics.
-
Executive Function Enhancement for Young Children with Down Syndrome
A caregiver-guided program for kids with Down syndrome aged up to 11 to strengthen their thinking skills during early childhood.
-
Center for Bat One Health: investigating bat health and spillover risk
A center in West Africa and the U.S. will study how bat biology and environmental stressors influence virus shedding and the chance of viruses jumping to people.
-
Center for Bat One Health Investigations and Outbreak Response
A national research center will study how bat stress from heat and human activity affects bat biology and viruses to understand spillover risks to people.
-
Center for Bat One Health Investigations, Research, and Outbreak Response
A center focused on how stressors like heat and human activity affect bats and the viruses they carry, to help prevent spillover to people.
-
Executive Function Support for Young Children with Down Syndrome
A caregiver-led program helps young children with Down syndrome build executive function skills during a 12-week period.
-
How malaria spreads and resists treatment in different parts of Burkina Faso
This project looks at how different mosquitoes, parasites, and human factors shape malaria risk across communities in Burkina Faso.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.